Ian Krop

Ian Krop is a breast oncologist with extensive expertise in HER2-targeted therapy and antibody-drug conjugate development across the HER2-expression spectrum. He has been a key investigator in clinical programs evaluating T-DXd in HER2-low disease and has contributed seminal work on the biology and clinical significance of low-level HER2 expression. His earlier research on T-DM1 mechanisms and resistance informed the development of next-generation HER2-directed ADCs, and he leads studies on HER2-low in the neoadjuvant and adjuvant settings.